Quantcast

Latest Nebulizer Stories

2009-02-10 07:30:00

MIDLOTHIAN, Va., Feb. 10 /PRNewswire/ -- Today, PARI Respiratory Equipment launched two updated continuing education classes, rounding out their free learning program with seven classes for respiratory therapists, nurses, case managers, and pharmacists. The classes are designed as group programs that are pre-approved for continuing education units by the Commission for Case Manager Certification (CCMC), American Association of Respiratory Care (AARC), Florida State Board of Nursing, and the...

2009-02-05 14:04:00

Mexico City-based distributor of Omron products becomes a wholly-owned subsidiary of Omron Healthcare, Inc. BANNOCKBURN, Ill., Feb. 5 /PRNewswire/ -- Omron Healthcare, Inc. (OHI), a leading marketer of blood pressure monitors in North America, today announced it has completed the acquisition of M&M Medi-Medics, S.A. De C.V., a privately-held healthcare diagnostics distributor, based in Mexico City, Mexico. "Omron Healthcare is excited about this acquisition and we're looking forward...

2008-12-15 12:20:00

JEFFERSON, N.C., Dec. 15 /PRNewswire/ -- Inhalers used for delivering albuterol, a fast-acting bronchial dilator, currently use propellants such as ozone-depleting CFC's, which are banned by the FDA beginning December 31st, 2009, or replacement HFA's. Both propellants are also used as industrial refrigerants and eject the medicine, albuterol, at near-supersonic speeds. The Next Safety device supplies medication in a stream of air by ejecting the medication from a microfluidic pump...

2008-12-04 14:02:00

BANNOCKBURN, Ill., Dec. 4 /PRNewswire/ -- Omron Healthcare, Inc. reminds consumers to take full advantage of the remaining dollars left in Flex- Spending Accounts (FSA's) before they expire by purchasing products to take control of their personal and family health such as home blood pressure monitors and nebulizers. (Photo: http://www.newscom.com/cgi-bin/prnh/20081204/AQTH541-a) (Photo: http://www.newscom.com/cgi-bin/prnh/20081204/AQTH541-b) As 2009 health benefit...

2008-11-12 09:00:10

MIDLOTHIAN, Virginia, Nov. 12 /PRNewswire/ -- On Saturday, November 15, PARI Respiratory Equipment will be featured on the ABC Family show Today's Family, as part of their "Breathe Easier" series. PARI is highlighted as a leading medical device company that provides patients, such as COPD sufferers, with effective nebulizers and compressors that deliver needed medications directly to the lungs. "Our vision is to improve the lives of those affected by respiratory diseases and those who care...

2008-11-10 15:00:07

MONTEREY, Calif., Nov. 10 /PRNewswire/ -- PARI Pharma GmbH has successfully completed Phase I and Phase II clinical trials comparing its proprietary PARI Tobramycin 100 (150mg/1.5mL) formulation delivered via a customized Investigational eFlow Nebulizer System to TOBI (tobramycin 300mg/5mL) delivered with the PARI LC PLUS jet nebulizer. While key deposition and safety thresholds were maintained, the marked difference was a reduction in the average inhalation time to 4 - 4 1/2 minutes for the...

2008-10-28 15:00:29

MIDLOTHIAN, Va., Oct. 28 /PRNewswire/ -- Today, PARI Respiratory Equipment presented a comparative study of three commercially available, breath-enhanced nebulizers and their in-vitro performance and delivery efficiency of budesonide inhalation suspension (Pulmicort Respules, AstraZeneca). Conclusions from the in-vitro study show that the LC Sprint Reusable Nebulizer delivered the shortest treatment times, with an average of 4.9 minutes, and had the highest respirable drug delivery rate....

2008-10-22 12:00:51

MIDLOTHIAN, Va., Oct. 22 /PRNewswire/ -- At CHEST 2008, PARI Respiratory Equipment will present a comparative study of three commercially available, breath-enhanced nebulizers and their in-vitro performance and delivery efficiency of budesonide inhalation suspension (Pulmicort Respules, AstraZeneca). "Our goal in testing various breath-enhanced nebulizers is to help clinicians consider respirable drug delivery rate to ensure patients receive clinically effective doses," said Lisa Cambridge,...

2008-10-13 09:00:09

Kamada, a biopharmaceutical company, has reported positive data from its Phase II study evaluating inhaled Alpha-1 Antitrypsin delivered via an investigational eFlow Nebulizer System, in the treatment of cystic fibrosis. The results demonstrate the product has an excellent safety profile and shows promising signs of efficacy, as indicated by a reduction in lung inflammation, the company said. The Phase II trial was a double-blind, placebo-controlled study, performed at the Cystic Fibrosis...

2008-10-12 12:00:04

Kamada (TASE:KMDA), a biopharmaceutical company engaged in the development, manufacturing and marketing of specialty life-saving therapeutics, announced today positive data from its Phase II study evaluating inhaled Alpha-1 Antitrypsin (AAT) delivered via an Investigational eFlow(R) Nebulizer System (PARI Pharma GmbH), in the treatment of cystic fibrosis. The results demonstrate the product has an excellent safety profile and shows promising signs of efficacy, as indicated by a reduction in...


Word of the Day
mallemaroking
  • Nautical, the visiting and carousing of sailors in the Greenland ships.
This word is apparently from a confusion of two similar Dutch words: 'mallemerok,' a foolish woman, and 'mallemok,' a name for some persons among the crew of a whaling vessel.